,
, Massachusetts General Hospital
Service d'Oncologie Médicale Thoracique et Digestive, Hôpital Laënnec, INSERM U1019, CIIL Institut Pasteur de, p.59000 ,
Avenue Oscar Lambret, F-59000 Lille, France. 9 Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank, Chirurgie Thoracique et Transplantation pulmonaire ,
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, vol.21, pp.2636-2680, 2003. ,
Diagnosis and prognosis-review of biomarkers for mesothelioma, Ann Transl Med, vol.5, p.244, 2017. ,
Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011. ,
Diagnostic value of neurotrophin expression in malignant pleural effusions, Exp Ther Med, vol.2, pp.941-947, 2011. ,
Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation, Clin Chim Acta, vol.352, pp.49-74, 2005. ,
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma, Eur Respir J, vol.41, pp.706-721, 2013. ,
Neurotrophin system activation in pleural effusions, Growth Factors, vol.28, pp.221-252, 2010. ,
BDNF: an oncogene or tumor suppressor?, Anticancer Res, vol.37, pp.3983-90, 2017. ,
Therapeutic potentials of BDNF/TrkB in breast Cancer; current status and perspectives, J Cell Biochem, vol.118, pp.2502-2517, 2017. ,
Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin Pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, vol.387, pp.1405-1419, 2016. ,